Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma

Rischin, Danny; Porceddu, Sandro; Peters, Lester J.; Martin, Jarad; Corry, June; Weih, LeAnn

doi:10.1002/hed.10396

Cited by 117 publications

(110 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other published series also reported a median survival time of 9-30 months. [14][15][16][17] The median survival time of 29.3 months and the three-year progressionfree survival rate of 41 per cent in the present cohort are consistent with those of published series. A summary of published data on the characteristics, treatment and outcomes of sinonasal undifferentiated carcinoma patients is given in Table III.…”

Section: Discussionsupporting

confidence: 92%

“…The two-year overall survival rate of 64 per cent in a cohort of patients treated with induction chemotherapy followed by radiochemotherapy reported by these authors was comparable to the results of different surgical series. 14 In the present series, six patients were treated with a similar approach: neoadjuvant chemotherapy followed by definitive RT (with or without concurrent chemotherapy). Neoadjuvant chemotherapy reduced the tumour size, and thus helped in RT planning for these patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A multimodality approach to sinonasal undifferentiated carcinoma: a single institute experience

et al. 2016

View full text Add to dashboard Cite

Background: Sinonasal undifferentiated carcinoma is a rare aggressive tumour arising from the Schneiderian epithelium lining the sinonasal tract. Although considered the cornerstone of therapy, surgical resection can only be performed in a limited number of patients. This report describes the experience of treating sinonasal undifferentiated carcinoma with a multimodality approach.Method: The treatment charts of sinonasal undifferentiated carcinoma patients treated at a tertiary care centre from 2004 to 2012 were retrospectively reviewed.Results: A total of 16 sinonasal undifferentiated carcinoma patients with a median age at diagnosis of 47.5 years (range 8-65 years) were included: 19 per cent had neck nodal metastasis at presentation. Four patients (25 per cent) underwent surgery: of these, two had post-operative radiotherapy, one had pre-operative radiotherapy and one had adjuvant chemotherapy alone. Six patients (38 per cent) received definitive radiotherapy: five had received neoadjuvant chemotherapy to reduce tumour size and help in radiotherapy planning, while four (25 per cent) received palliative radiotherapy. The median follow up was 10.4 months (range 1-42.5 months). The estimated median progression-free survival time was 29.3 months. One-and three-year progression-free survival rates were 77 per cent and 41 per cent, respectively.Conclusion: Surgery is the best treatment option for sinonasal undifferentiated carcinoma, although most patients require post-operative radiotherapy for advanced disease and close tumour margins. Definitive radiotherapy with or without chemotherapy may be suitable for patients with inoperable locally advanced disease. Elective nodal irradiation to address the high nodal involvement rates should be considered to improve the survival rate.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

A multimodality approach to sinonasal undifferentiated carcinoma: a single institute experience

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Induction chemotherapy usually consists of both platinum (e.g., cisplatin) and either 5-FU (i.e., fluorouracil) or etoposide, whereas chemotherapy concurrent with radiation may be restricted to platinum alone (e.g., cisplatin) out of concern for tissue toxicity 7,11,20 . Undifferentiated tumors such as SNUC may not be subject to such rapid deleterious cell repopulation that more differentiated tumors may experience following chemotherapy, and thus they may have an improved response to such treatment.…”

mentioning

confidence: 99%

“…7,24 Of further possible benefit, induction chemotherapy may reduce SNUC tumor bulk in areas near vital radiation dose-limiting structures (e.g., optic chiasm) and thus may optimize outcomes achievable with radiation treatment. 7 Specific chemotherapeutic agents and the distinction between induction and concurrent chemotherapy were not evaluated in the present study because information about their use is not available in the SEER database. Given the often poor prognosis of SNUC despite aggressive application of currently available treatments, numerous novel therapies have been tried with limited success including neoadjuvant selective intra-arterial cisplatin, autologous bone marrow transplant, and boron neutron capture therapy.…”

mentioning

confidence: 99%

Incidence and Survival Patterns of Sinonasal Undifferentiated Carcinoma in the United States

Chambers¹,

Lehmann²,

Remenschneider³

et al. 2014

J Neurol Surg B

View full text Add to dashboard Cite

“…Sinonasal undifferentiated carcinoma is particularly difficult to treat [13][14][15][16]. Patients with resectable tumours are offered surgery followed by chemoradiation.…”

Section: Discussionmentioning

confidence: 99%

Undifferentiated Sinonasal Carcinoma—Case Report

Todorović¹,

Boljevic²

2017

JPP

View full text Add to dashboard Cite

SNUC (undifferentiated sinonasal carcinoma) is a rare tumor. The exact cause of this cancer is not known. Patients usually have signs and symptoms of bleeding from the nose, runny nose, duplicate photos, symptoms of chronic sinus infections and nose, nasal obstruction, or facial pain. We reported a case of seventy year old patient with sinonasal undifferentiated carcinoma in the right maxillary sinus. Six months ago, the patient was conducted operations polyp in the right nasal hall. He had pain in the right side of his face and swelling in the mouth in the area of the upper jaw on the right side. The patient was operated tumor of the right maxillary sinus, with expansion in the ethmoid sinus, nasal cavity and infratemporal space. The neck dissection was done on the same side. Postoperatively, he received radiation therapy and chemotherapy. SNUC is very rare aggressive cancer that requires aggressive therapy. This cancer is considered in need of modified maxillary sinuses, as well as for modified sinus in polyps or after the operation of the same. Despite extensive surgery, radio therapy and implemented chemotherapy, the prognosis of these tumors is very poor.

show abstract

Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma

Abstract: Induction chemotherapy followed by concurrent chemoradiation is promising treatment strategy for SNUC.

Cited by 117 publications

References 18 publications

A multimodality approach to sinonasal undifferentiated carcinoma: a single institute experience

A multimodality approach to sinonasal undifferentiated carcinoma: a single institute experience

Incidence and Survival Patterns of Sinonasal Undifferentiated Carcinoma in the United States

Undifferentiated Sinonasal Carcinoma—Case Report

Contact Info

Product

Resources

About